Welcome to nudaPETides. Coming soon.

The prescribing platform for veterinary peptide medicine. For licensed veterinarians.

Formulary
EndocrineDogTier B

Sermorelin

Growth hormone releasing hormone analog. Restores physiological pulsatile GH release.

Weight

3,358 Da

Half-life

10 to 20 minutes

Chain

29 amino acids

Studies

18 referenced. Latest 2022.

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library. Request access.

Overview

Sermorelin is a 29-amino acid analog of growth hormone releasing hormone. It works upstream of the pituitary to stimulate the animal's own growth hormone release. Physiologic pulses. Preserved feedback control. No supraphysiologic peaks.

The senior dog vitality peptide. That is the shorthand every prescriber remembers.

Mechanism of action

  1. 01Binds the GHRH receptor on somatotroph cells in the anterior pituitary.
  2. 02Triggers endogenous pulsatile growth hormone release.
  3. 03Preserves negative feedback via IGF-1 and somatostatin.
  4. 04Restores age-related decline in GH pulse amplitude.
  5. 05Downstream IGF-1 supports muscle mass, coat quality, and cellular repair.

Molecular data

PropertyValue
Molecular weight3,358 Da
Chain length29 amino acids
TypeGHRH analog
RouteSubcutaneous injection

Species applicability

Dog

Age-related GH decline mirrors human physiology. Muscle wasting in senior dogs. Recovery adjunct after major surgery. Cognitive dysfunction syndrome supportive care. Sermorelin is dog-only in the current nudaPETides formulary. Feline endocrine biology differs and safety data is thinner.

Prescribing indications

EndocrineEFFECTIVE

Senior dogs with muscle wasting and sarcopenia.

RecoveryEFFECTIVE

Post-surgical recovery in older patients.

NeurologicEMERGING

Cognitive dysfunction syndrome adjunct.

Dosing framework

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library.

Request access

Reconstitution and administration

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library.

Request access

Interactions

Sermorelin + Ipamorelin + CJC-1295COMPATIBLESequential dosing recommended.

What to expect

Week 2 to 4Improved energy. Improved appetite.
Week 4 to 8Coat quality changes. Improved lean muscle tone.
Week 8 to 12Owner reports better mobility and stamina.

Safety profile

Endogenous pulsatile release preserves feedback control. Contraindicated in active malignancy given uncertain effects on tumor GH signaling.

Research library

Prakash A, Goa KL. Sermorelin: a review of its use in idiopathic growth hormone deficiency. BioDrugs.PubMedWalker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency. Clinical Interventions in Aging.PMCCorpas E et al. GHRH(1-29) twice daily reverses decreased GH and IGF-I levels in old men. Journal of Clinical Endocrinology and Metabolism.JournalKhorram O et al. Effects of subcutaneous GHRH(1-29) on somatotropic and HPA axes in older men. Neurobiology of Aging.PubMed

Related peptides

Ipamorelin + CJC-1295

Endocrine

View

NAD+

Longevity

View

BPC-157

Recovery

View

Regulatory footing

This monograph describes a compounded veterinary medication available by prescription only through a licensed veterinarian inside an active veterinarian-client-patient relationship. Not FDA-approved for animal or human use. Compounded on a patient-specific basis under FDA Guidance for Industry #256. For educational use by licensed veterinarians. Not intended for consumer self-prescribing.

For licensed veterinarians only. Compounded under FDA GFI 256. Not FDA-approved.